KalVista’s Funding Move: A Double-Edged Sword for Investors
Published on 09/25/2025 at 08:00 | Redaktion boerse-global.de
KalVista Pharmaceuticals finds itself navigating conflicting market currents following the announcement of a significant capital raise. The biotech firm secured fresh funding to support the global commercialization of its newly approved drug EKTERLY®, but the financing structure triggered an immediate negative reaction from shareholders, sending the stock sharply lower in after-hours trading.
The company successfully placed $125 million in convertible senior notes, exceeding its initial target of $110 million. Additionally, KalVista granted the issuers an option to purchase up to an extra $18.75 million in notes. Proceeds are earmarked for general corporate purposes, working capital, and advancing the commercial rollout of EKTERLY®. These 3.25% notes mature in 2031 and carry a conversion price of approximately $16.81 per share, representing a substantial 30% premium to Wednesday’s closing price.
This... Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
